Per September 2017 around 70 percent of the Indonesian population participates in the government's universal healthcare program (in Indonesian: Jaminan Kesehatan Nasional or JKN), a program that was implemented by the social security agency Badan Penyelenggara Jaminan Sosial Kesehatan (BPJS) in early 2014. This government-subsidized program aims to provide all Indonesian citizens with access to a wide range of health services by 2019.

Read more ›

For its raw materials the pharmaceutical industry of Indonesia is highly dependent on imports. Around 90 percent of medicines' raw materials, roughly IDR 7 trillion (approx. USD $526 million), may be imported this year. Meanwhile, given the Indonesian government is eager to develop its universal health care program (launched in 2014), demand for pharmaceutical products in Indonesia is expected to rise further. Total clients under the national health insurance program is expected to rise from 162 million in 2015 to 186 million in 2016. By the year 2019 the government wants to provide universal health care to all Indonesians.

Read more ›

There is a growing mismatch between claims paid and premiums received by Indonesia's Healthcare and Social Security Agency (Badan Penyelenggara Jaminan Sosial, or BPJS Kesehatan). This year the deficit could reach IDR 9.8 trillion (approx. USD $731 million), leading to concern about the financial sustainability of the program and the need to search for additional and innovative ways to fund Indonesia's National Health Insurance (Jaminan Kesehatan Nasional, or JKN) program.

Read more ›